Ibrutinib as the Unifying Culprit: A Case Report of Multisystem Complications in an Elderly Patient With Low-Grade B-Cell Lymphoproliferative Disorder. (PubMed, Cureus) - Oct 2, 2026 - "While highly effective, its adverse effect profile is broad and potentially life-threatening, particularly in elderly patients with multiple comorbidities. We report an 82-year-old woman with a seven-year history of CD5-negative low-grade B-cell LPD and IgM paraproteinaemia, managed sequentially with rituximab and ibrutinib...The concurrent prescription of apixaban for AF and clarithromycin for lower respiratory tract infection (LRTI) created critical drug interaction hazards. A review of her clinical course suggests that ibrutinib may have been the unifying causative agent across multiple organ systems. This case highlights the importance of vigilant monitoring for ibrutinib-associated adverse events in elderly patients, the complexity of anticoagulation decisions in the setting of ibrutinib-induced AF, and the indispensable role of multidisciplinary team (MDT) management. Clinicians should maintain a high index of suspicion for ibrutinib as the..."
Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Infectious Disease • Lymphoplasmacytic Lymphoma • Oncology • Respiratory Diseases • Waldenstrom Macroglobulinemia • CD5
|
|
Ahmed Elnour; Khalid Ghalib; Mohamed Ali; Nada Eltigani Hassan Mahgoub; Pedro Arregui
|